Amarin's Omega-3 Fair Trade Complaint Questions US Dietary Ingredient Standards
This article was originally published in The Pink Sheet
Amarin's recent fair trade complaint targetting purified EPA dietary supplements and formulations also raises broader questions about using synthetic dietary ingredients in consumer supplements and the extent to which a substance’s identification in an IND precludes subsequent use as a dietary ingredient.
You may also be interested in...
National Advertising Division, in rare review of an Rx drug firm’s challenge of supplement ad claims, reported Innovix Pharma pulled health claims for OmegaVia brand supplements challenged by Amarin. Innovix prevailed in defending its labeling as accurate and its name as not false advertising.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.
Seeking to protect its competitive interests, Vascepa marketer asks the US International Trade Commission to investigate importation and sale of synthetically produced omega-3 products by 18 companies; complaint asserts the products at issue are unapproved new drugs that are illegally being marketed as dietary supplements.